medigraphic.com
Revista Médica Sinergia

2020, Número 03

<< Anterior Siguiente >>

Revista Médica Sinergia 2020; 5 (03)


Diagnóstico y manejo del síndrome antifosfolípido catastrófico

Hernández VA, Arias VR, Miranda VL

Idioma: Español
Referencias bibliográficas: 21
Paginas: 394-394
Archivo PDF: 134.19 Kb.


RESUMEN

El síndrome antifosfolípido es una patología heterogénea con manifestaciones trombóticas, obstétricas y no trombóticas, asociada con la presencia de diferentes anticuerpos antifosfolípido. Su forma catastrófica es infrecuente, está relacionada en la mayoría de los casos con un factor desencadenante y se manifiesta con la presencia de múltiples trombos que pueden estar alojados en cualquier parte del cuerpo y que histológicamente se presentan como una microangiopatía trombótica. Esta enfermedad debe ser reconocida oportunamente para la instauración inmediata de triple terapia, lo cual disminuye su mortalidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Mezhov V, Segan JD, Tran H, Cicuttini FM. Antiphospholipid syndrome: a clinical review. Medical Journal of Australia. 2019 07 04;211(4):184-188. https://doi.org/10.5694/mja2.50262

  2. Riva N, Gatt A. Update on the Diagnosis and Anticoagulant Treatment of the Antiphospholipid Syndrome. EMJ Rheumatol. 2019;6(1):101-11.

  3. Vadgama TS, Smith A, Bertolaccini ML. Treatment in thrombotic antiphospholipid syndrome: a review. Lupus. 2019 Sep;28(10):1181-8.https://doi.org/10.1177/0961203319864163

  4. Bijilsma J, Hachulla E. EULAR Textbook on Rheumathic Diseases. 3rd ed. London: BMJ Publishing Group Ltd; 2018.

  5. Schreiber K, Sciascia S, de Groot PG, Devreese K, Jacobsen S, Ruiz-Irastorza G, et al. Antiphospholipid syndrome. Nat Rev Dis Primers. 2018 Jan 11; 4:17103. https://doi.org/10.1038/nrdp.2018.5

  6. Kazzaz NM, McCune WJ, Knight JS. Treatment of catastrophic antiphospholipid syndrome. Current Opinion in Rheumatology. 2016 05;28(3):218-227. https://doi.org/10.1097/bor.0000000000000269

  7. Cervera R, Rodríguez-Pinto I, Espinosa G. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: a comprehensive review. J Autoimmun. 2018 Aug; 92:1-11. https://doi.org/10.1016/j.jaut.2018.05.007

  8. Unlu O, Erkan D. Catastrophic Antiphospholipid Syndrome: Candidate Therapies for a Potentially Lethal Disease. Annual Review of Medicine. 2017 01 14;68(1):287-296. https://doi.org/10.1146/annurev-med- 042915-102529

  9. Limper M, Scirè CA, Talarico R, Amoura Z, Avcin T, Basile M, Burmester G, Carli L, Cervera R, Costedoat-Chalumeau N, Doria A, Dörner T, Fonseca JE, Galetti I, Hachulla E, Launay D, Lourenco F, Macieira C, Meroni P, Montecucco CM, Moraes-Fontes MF, Mouthon L, Nalli C, Ramoni V, Tektonidou M, van Laar JM, Bombardieri S, Schneider M, Smith V, Vieira A, Cutolo M, Mosca M, Tincani A. Antiphospholipid syndrome: state of the art on clinical practice guidelines. RMD Open. 2018 Oct;4(Suppl 1):e000785. https://doi.org/10.1136/rmdopen-2018-000785

  10. Rodríguez-Pinto I, Moitinho M, Santacreu I, Shoenfeld Y, Erkan D, Espinosa G, et al. Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev. 2016 Dec;15(12):1120-4. https://doi.org/10.1016/j.autrev.2016.09.010

  11. Carmi O, Berla M, Shoenfeld Y, Levy Y. Diagnosis and management of catastrophic antiphospholipid syndrome. Expert Rev Hematol. 2017 Apr;10(4):365-74.https://doi.org/10.1080/17474086.2017.1300522

  12. Rodríguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: the current management approach. Best Pract Res Clin Rheumatol. 2016 Apr;30(2):239-49. https://doi.org/10.1016/j.berh.2016.07.004

  13. Rodriguez-Pintó I, Espinosa G, Cervera R. Catastrophic antiphospholipid syndrome: The current management approach. Best Practice & Research Clinical Rheumatology. 2016 04;30(2):239- 249. https://doi.org/10.1016/j.berh.2016.07.004

  14. Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018 May 24;378(21):2010-21.https://doi.org/10.1056/NEJMra1705454

  15. Firestein GS, Budd R, Gabriel SE McInnes IB, O´Dell JR. Kelley and Firestein´s Textbook of Rheumatology. 10th ed. PA: Elsevier Health Sciences; 2017.

  16. Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases. 2019 05 15;78(10):1296-1304. https://doi.org/10.1136/annrheumdis-2019-215213

  17. Legault K, Schunemann H, Hillis C, Yeung C, Ak EA, Carrier M, et al. McMaster RARE􀇦Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 Jun 7;16(8),1656-64.https://doi.org/10.1111/jth.14192

  18. Özgür G, Beyan C. Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. Transfusion and Apheresis Science. 2018 02;57(1):13- 15. https://doi.org/10.1016/j.transci.2018.02.008

  19. Rodríguez-Pintó I, Lozano M, Espinosa G, Cervera R. Plasma exchange in catastrophic antiphospholipid syndrome. Presse Med. 2019 Nov 4. pii: S0755-4982(19)30462-2.

  20. Tinti MG, Carnevale V, Inglese M, Molinaro F, Bernal M, Migliore A, et al. Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. Clin Exp Med. 2019 Aug;19(3):281-8. https://doi.org/10.1007/s10238-019-00565-8

  21. Rodríguez-Pintó I, Cervera R, Espinosa G. Rituximab and its therapeutic potential in catastrophic antiphospholipid syndrome. Ther Adv Musculoskelet Dis. 2015 Feb; 7(1):26-30. https://doi.org/10.1177/1759720X14554793




2020     |     www.medigraphic.com